Antiviral treatment to prevent chronic hepatitis B or C-related hepatocellular carcinoma

doi:10.5501/wjv.v1.i6.174

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 1, Issue 6

This Article

Citation of this article

Corresponding Author of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (5869)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-2) series, Tables (1-1) series.

Item

Count

PDF

502

HTML

4920

Figures (1-2)

314

Tables (1-1)

133

Sum=5869

Dec 12, 2012 (publication date) through Apr 25, 2024

Times Cited of This Article

Times Cited (25)

Journal Information of This Article

Publication Name

World Journal of Virology

ISSN

2220-3249

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Review

World J Virol. Dec 12, 2012; 1(6): 174-183
Published online Dec 12, 2012. doi: 10.5501/wjv.v1.i6.174

Full Size Figure Download Figure

Figure 1 Flowchart of therapy choice for patients with chronic hepatitis B virus infection. ALT: Alanine aminotransferase; HBeAg: Hepatitis B e antigen; HCC: Hepatocellular carcinoma; HBV: Hepatitis B virus; IFN: Interferon; NAs: Nucleos(t)ide analogues; ULN: Upper limit of normal.

Citation: Chen LP, Zhao J, Du Y, Han YF, Su T, Zhang HW, Cao GW. Antiviral treatment to prevent chronic hepatitis B or C-related hepatocellular carcinoma. World J Virol 2012; 1(6): 174-183
URL: https://www.wjgnet.com/2220-3249/full/v1/i6/174.htm
DOI: https://dx.doi.org/10.5501/wjv.v1.i6.174